National Alzheimer's Project Act

National Alzheimer's Project Act. The act is a landmark United States federal law signed by President Barack Obama in January 2011. It established a strategic national framework to accelerate the development of treatments and improve care for individuals with Alzheimer's disease. The law mandated the creation of a comprehensive plan to coordinate Alzheimer's disease research and services across the federal government.

Legislation and Purpose

The legislation was introduced by Senator Susan Collins of Maine and co-sponsored by Senator Evan Bayh of Indiana. It received broad bipartisan support, passing both the United States Senate and the United States House of Representatives by unanimous consent. The primary purpose was to address the escalating public health crisis posed by Alzheimer's disease, which was placing an immense burden on the Medicare and Medicaid programs. The act aimed to create a coordinated national strategy under the leadership of the Department of Health and Human Services.

Key Provisions

A central provision was the establishment of the National Alzheimer's Project Office within the Office of the Secretary of Health and Human Services. The act also created the Advisory Council on Alzheimer's Research, Care, and Services, composed of experts from federal agencies and the public. It required the development and annual updating of a National Plan to Address Alzheimer's Disease. Furthermore, the law mandated that the Secretary of Health and Human Services evaluate all federally funded programs related to Alzheimer's disease and report to the United States Congress on research priorities and outcomes.

Implementation and Impact

Implementation began swiftly with the first National Plan to Address Alzheimer's Disease released in 2012. The plan set an ambitious goal to prevent and effectively treat Alzheimer's disease by 2025. The work of the Advisory Council on Alzheimer's Research, Care, and Services has led to numerous recommendations integrated into federal policy. A significant impact has been the increased coordination among agencies like the National Institutes of Health, the Centers for Disease Control and Prevention, and the Administration for Community Living. The act also elevated the disease as a top public health priority, influencing initiatives like the BRAIN Initiative.

Alzheimer's Disease Research

The act has profoundly shaped the national Alzheimer's disease research agenda. It led to significant increases in funding through the National Institute on Aging and other National Institutes of Health institutes. Research priorities expanded to include earlier detection, risk reduction, and the study of related dementias like frontotemporal dementia and Lewy body dementia. Large-scale projects such as the Alzheimer's Disease Neuroimaging Initiative and the Alzheimer's Disease Sequencing Project received enhanced support. The research strategy also emphasized translational science to move discoveries from the laboratory into clinical trials more rapidly.

Funding and Authorization

While the act itself did not appropriate specific funds, it authorized the necessary activities and required annual reporting on federal expenditures. Subsequent congressional actions, influenced by the act's framework, led to substantial funding increases. Annual appropriations for Alzheimer's disease research at the National Institutes of Health grew from around $450 million in 2011 to over $3.7 billion in 2023. The act's authorization has been extended multiple times, ensuring the continuation of the National Alzheimer's Project Office and the strategic plan. This sustained commitment has involved key congressional figures from committees like the United States Senate Appropriations Subcommittee on Labor, Health and Human Services, Education, and Related Agencies.

Category:United States federal health legislation Category:2011 in American law Category:Alzheimer's disease